Next |
home / stock / myov / myov message board
Subject | By | Source | When |
---|---|---|---|
What a run from the $7's a few | Cosa | investorshub | 10/28/2022 9:01:02 PM |
I was hoping for $5. more a share | MDizzle | investorshub | 10/24/2022 11:50:14 AM |
Woohoo Cheers!! | Cosa | investorshub | 10/24/2022 7:17:58 AM |
Woohoo Cheers!! | Cosa | investorshub | 10/24/2022 7:17:54 AM |
Nice! patience always pays. Agree it will | Cosa | investorshub | 10/10/2022 8:05:39 PM |
Lol. No worries it will make a | Cosa | investorshub | 10/04/2022 11:48:01 PM |
I also took profits on most of the | Dallas-Cowboys | investorshub | 10/04/2022 8:28:47 PM |
Yep taking profits here as don't want to | rosemountbomber | investorshub | 10/04/2022 7:15:33 PM |
Taking more off the top. What a | Cosa | investorshub | 10/03/2022 6:37:39 PM |
The tell in that sad situation was the | nferna | investorshub | 10/03/2022 1:08:19 PM |
What we will see is if Pfizer wants | Dallas-Cowboys | investorshub | 10/03/2022 12:57:26 PM |
Sorry to hear that I dont think this | Dallas-Cowboys | investorshub | 10/03/2022 12:51:17 PM |
I have tried to put all the details | rosemountbomber | investorshub | 10/03/2022 12:10:54 PM |
Not aware of that what happened | Dallas-Cowboys | investorshub | 10/03/2022 11:52:50 AM |
Hope there is no screw up like Peter | rosemountbomber | investorshub | 10/03/2022 11:02:41 AM |
That would value around 2.3 billion no way | Dallas-Cowboys | investorshub | 10/03/2022 12:47:17 AM |
Maybe. The problem (for $MYOV minority shareholders) is | DewDiligence | investorshub | 10/03/2022 12:32:27 AM |
It is just getting started first volley they | Dallas-Cowboys | investorshub | 10/03/2022 12:29:21 AM |
https://finance.yahoo.com/news/myovant-sciences-special-committee-board-23360069 | DewDiligence | investorshub | 10/03/2022 12:15:06 AM |
I believe they want to be taken over | Dallas-Cowboys | investorshub | 09/30/2022 9:21:05 AM |
News, Short Squeeze, Breakout and More Instantly...
Myovant Sciences Ltd. Company Name:
MYOV Stock Symbol:
NYSE Market:
NEW YORK, NY / ACCESSWIRE / October 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myovant Sciences, Ltd. ("Myovant" or "the Company") (NYSE:MYOV). Investors who purchased Myovant securities are encouraged to obtain additional infor...
Third fiscal quarter 2022 total revenue of $100.2 million ; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX ® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume ...
MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences MYOV SPECIAL ALERT: Julie & Holleman Investigates Potential Legal Claims Related to Take-Private Acquisition of Myovant Sciences PR Newswire ...